Related Experiment Videos
Management strategies for respiratory syncytial virus infections in infants
1Department of Infectious Diseases, Children's National Medical Center, Washington, DC, USA.
Insights
Respiratory syncytial virus (RSV) lower respiratory tract infection management in infants is mainly supportive. Studies suggest aerosolized ribavirin may benefit long-term pulmonary sequelae, though evidence remains debated.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pulmonology
Background:
- Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in infants.
- Current management is primarily supportive and symptomatic, focusing on hydration and respiratory support.
- Concerns exist regarding long-term pulmonary sequelae following early-life RSV infections.
Purpose of the Study:
- To review current management strategies for RSV lower respiratory tract infection in infants.
- To evaluate the efficacy of antiviral and immunotherapeutic agents.
- To explore the potential long-term benefits of ribavirin on pulmonary sequelae.
Main Methods:
- Review of existing literature and clinical data on RSV infection management.
- Analysis of outcomes associated with supportive care, bronchodilators, antiviral therapy (ribavirin), and immunotherapy.
- Examination of data regarding long-term pulmonary sequelae and potential interventions.
Main Results:
- Supportive care, including hydration and monitoring, is the cornerstone of infant RSV management.
- Alpha- or beta(2)-adrenergic agonist bronchodilators may offer symptomatic relief but their role is controversial.
- Aerosolized ribavirin's role in improving clinical outcomes and reducing long-term sequelae is under investigation, with mixed study results.
Conclusions:
- Management of RSV lower respiratory tract infection in infants relies heavily on supportive and symptomatic care.
- While immunotherapy has shown antiviral effects, clinical outcomes have been disappointing.
- Further research is needed to clarify the role of ribavirin in mitigating long-term pulmonary sequelae after RSV infection.
Abstract:
Management of respiratory syncytial virus lower respiratory tract infection in infants is predominantly supportive and symptomatic. Outpatient management requires close attention to feeding, oral hydration, and monitoring of fever, behavior, and respiratory effort. In the small proportion of patients who need hospitalization, clinicians are concerned primarily with oxygenation and the possibility of oxygen desaturation. Appropriate interventions depend on the level of oxygenation as indicated by pulse oximetry or arterial blood gases. Hydration and symptomatic treatment with alpha- or ss(2 )-adrenergic agonist bronchodilators may lessen the work of breathing. The role of these agents remains controversial, however, and anticholinergic bronchodilators are considered ineffective. Current antiviral therapy is limited to aerosolized ribavirin. Immunotherapy with respiratory syncytial virus immune globulin or a monoclonal antibody has not been rewarding in terms of clinical outcome, although the antiviral effect of these agents has been impressive. There is concern about long-term pulmonary sequelae after respiratory syncytial virus lower respiratory tract infection early in life. Several recent studies, including new data reported here, suggest that ribavirin may have a beneficial effect on some of these sequelae, whereas other studies have failed to demonstrate any benefit. Future studies may help resolve this question.